These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30055781)

  • 21. Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors.
    Kuei A; Saab S; Cho SK; Kee ST; Lee EW
    World J Gastroenterol; 2015 Jul; 21(27):8271-83. PubMed ID: 26217079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review.
    Wright CL; Werner JD; Tran JM; Gates VL; Rikabi AA; Shah MH; Salem R
    J Vasc Interv Radiol; 2012 May; 23(5):669-74. PubMed ID: 22525023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increasing Yttrium-90 Dose Conformality Using Proximal Radioembolization Enabled by Distal Angiosomal Truncation for the Treatment of Hepatic Malignancy.
    Core JM; Frey GT; Sharma A; Bussone ST; Legout JD; McKinney JM; Lewis AR; Ritchie C; Devcic Z; Paz-Fumagalli R; Toskich BB
    J Vasc Interv Radiol; 2020 Jun; 31(6):934-942. PubMed ID: 32381352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors.
    Jia Z; Paz-Fumagalli R; Frey G; Sella DM; McKinney JM; Wang W
    J Gastroenterol Hepatol; 2017 Sep; 32(9):1617-1623. PubMed ID: 28132407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microvascular injury in persistent gastric ulcers after yttrium-90 microsphere radioembolization for liver malignancies.
    Sun B; Lapetino SR; Diffalha SA; Yong S; Gaba RC; Bui JT; Koppe S; Garzon S; Guzman G
    Hum Pathol; 2016 Apr; 50():11-4. PubMed ID: 26997433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Partition Dosimetry and Outcomes of Metastatic Neuroendocrine Tumors after Yttrium-90 Resin Microsphere Radioembolization.
    Doyle PW; Workman CS; Grice JV; McGonigle TW; Huang S; Borgmann AJ; Baker JC; Taylor JE; Brown DB
    J Vasc Interv Radiol; 2024 May; 35(5):699-708. PubMed ID: 37871833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modified Radiation Lobectomy Strategy of Radioembolization for Right-Sided Unresectable Primary Liver Tumors.
    Yu Q; Wang Y; Ungchusri E; Pillai A; Liao CY; Fung J; DiSabato D; Baker T; Patel M; Van Ha T; Ahmed O
    J Vasc Interv Radiol; 2024 Jul; 35(7):989-997.e2. PubMed ID: 38490364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging.
    Wong CY; Qing F; Savin M; Campbell J; Gates VL; Sherpa KM; Lewandowski RJ; Nagle C; Salem R
    J Vasc Interv Radiol; 2005 Aug; 16(8):1101-6. PubMed ID: 16105922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma.
    Kis B; Shah J; Choi J; El-Haddad G; Sweeney J; Biebel B; Mellon E; Frakes JM; Hoffe SE; Fishman MN; Shridhar R
    J Vasc Interv Radiol; 2017 Feb; 28(2):254-259. PubMed ID: 27955832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver.
    Abdelmaksoud MH; Louie JD; Hwang GL; Kothary N; Minor DR; Sze DY
    J Vasc Interv Radiol; 2012 Mar; 23(3):323-30.e1. PubMed ID: 22277275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
    Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
    J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.
    Gangi A; Shah J; Hatfield N; Smith J; Sweeney J; Choi J; El-Haddad G; Biebel B; Parikh N; Arslan B; Hoffe SE; Frakes JM; Springett GM; Anaya DA; Malafa M; Chen DT; Chen Y; Kim RD; Shridhar R; Kis B
    J Vasc Interv Radiol; 2018 Aug; 29(8):1101-1108. PubMed ID: 30042074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Temporary Balloon Occlusion for Hepatic Arterial Flow Redistribution during Yttrium-90 Radioembolization.
    Meek J; Fletcher S; Gauss CH; Bezold S; Borja-Cacho D; Meek M
    J Vasc Interv Radiol; 2019 Aug; 30(8):1201-1206. PubMed ID: 31155499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Embolization of parasitized extrahepatic arteries to reestablish intrahepatic arterial supply to tumors before yttrium-90 radioembolization.
    Abdelmaksoud MH; Louie JD; Kothary N; Hwang GL; Kuo WT; Hofmann LV; Hovsepian DM; Sze DY
    J Vasc Interv Radiol; 2011 Oct; 22(10):1355-62. PubMed ID: 21961979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor Size and Watershed Area Correlate with Incomplete Treatment and Tumor Progression after Selective Radioembolization for Hepatocellular Carcinoma.
    Yu Q; Neale M; Ungchusri E; Rothenberger NJ; Liao C; Patel M; Pillai A; Navuluri R; Ahmed O; Ha TV
    J Vasc Interv Radiol; 2024 May; 35(5):712-721.e3. PubMed ID: 38336031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Selective internal radiotherapy (SIRT) for hepatocellular carcinoma].
    Antoch G; Mueller SP; Hamami M; Heusner TA; Ertle J; Hilgard P; Forsting M; Bockisch A
    Rofo; 2010 Aug; 182(8):660-70. PubMed ID: 20405369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of Yttrium-90 Radioembolization for Unresectable Combined Biphenotypic Hepatocellular-Cholangiocarcinoma.
    Malone CD; Gibby W; Tsai R; Kim SK; Lancia S; Akinwande O; Ramaswamy RS
    J Vasc Interv Radiol; 2020 May; 31(5):701-709. PubMed ID: 32127318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regional yttrium-90 microsphere treatment of surgically unresectable and chemotherapy-refractory metastatic liver carcinoma.
    Wong CY; Savin M; Sherpa KM; Qing F; Campbell J; Gates VL; Lewandowski RJ; Cheng V; Thie J; Fink-Bennett D; Nagle C; Salem R
    Cancer Biother Radiopharm; 2006 Aug; 21(4):305-13. PubMed ID: 16999596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.